Meissa Vaccines develops live attenuated vaccine candidates against respiratory viruses, including respiratory syncytial virus (RSV) and COVID-19, using its proprietary AttenuBlock platform.

Meissa Vaccines

Meissa Vaccines | 1,309 followers on LinkedIn. Taming Viruses with ​Synthetic Biology | Meissa is a private biotech company focused on the advancement of vaccines for respiratory viruses. Meissa was founded on proprietary technologies employing reverse genetics for rational design of more effective live attenuated vaccines. The technology is exclusively licensed from Emory University and Children’s Healthcare of Atlanta.

MEIS

COM:MEISSAVACCINES

Meissa Vaccines

locale

market

industry

website

crunchbase

linkedin

peer of

Metrics